Trends in Psychiatry and Psychotherapy
https://trends.org.br/article/doi/10.1590/2237-6089-2018-0047
Trends in Psychiatry and Psychotherapy
Original Article

Schizophrenia TreAtment with electRic Transcranial Stimulation (STARTS): design, rationale and objectives of a randomized, double-blinded, sham-controlled trial

Tratamento da esquizofrenia com estimulação transcraniana por corrente contínua (ETCC): fundamentação teórica e objetivos de um ensaio clínico randomizado, duplo-cego, controlado por simulação

Leandro Valiengo; Pedro Caldana Gordon; Juliana Barbosa de Carvalho; Rosa Maria Rios; Stephanie Koebe; Mauricio Henrique Serpa; Martinus van de Bilt; Acioly Lacerda; Helio Elkis; Wagner Farid Gattaz; André Russowsky Brunoni

http://dx.doi.org/10.1590/2237-6089-2018-0047 Trends Psychiatry Psychother, vol.41, n2, p.104-111, 2019
PDF
SciELO
Downloads: 0
Views: 463

Abstract

Abstract Introduction Schizophrenia is a severe mental disorder. While some antipsychotic medications have demonstrated efficacy in treating positive symptoms, there is no widely recognized treatment for negative symptoms, which can cause significant distress and impairment for patients with schizophrenia. Here we describe the rationale and design of the STARTS study (Schizophrenia TreAtment with electRic Transcranial Stimulation), a clinical trial aimed to test the efficacy of a non-pharmacological treatment known as transcranial direct current stimulation (tDCS) for treating the negative symptoms of schizophrenia Methods The STARTS study is designed as a randomized, sham-controlled, double-blinded trial evaluating tDCS for the treatment of the negative symptoms of schizophrenia. One-hundred patients will be enrolled and submitted to 10 tDCS sessions over the left dorsolateral prefrontal cortex (anodal stimulation) and left temporoparietal junction (cathodal stimulation) over 5 consecutive days. Participants will be assessed using clinical and neuropsychological tests before and after the intervention. The primary outcome is change in the Positive and Negative Syndrome Scale (PANSS) negative subscale score over time and across groups. Biological markers, including blood neurotrophins and interleukins, genetic polymorphisms, and motor cortical excitability, will also be assessed. Results The clinical results will provide insights about tDCS as a treatment for the negative symptoms of schizophrenia, and the biomarker investigation will contribute towards an improved understanding of the tDCS mechanisms of action. Conclusion Our results could introduce a novel therapeutic technique for the negative symptoms of schizophrenia. Clinical trial registration: ClinicalTrials.gov, NCT02535676 .

Keywords

Schizophrenia, electric stimulation therapy, randomized controlled trial, biological markers, transcranial stimulation

Resumo

Resumo Introdução A esquizofrenia é um transtorno mental grave. Embora alguns medicamentos antipsicóticos tenham demonstrado eficácia no tratamento de sintomas positivos, não há tratamento amplamente reconhecido para sintomas negativos, o que pode causar sofrimento e prejuízo significativos para pacientes com esquizofrenia. Aqui descrevemos a fundamentação teórica e o design do estudo STARTS (Schizophrenia TreAtment with electRic Transcranial Stimulation), um ensaio clínico destinado a testar a eficácia de um tratamento não farmacológico conhecido como estimulação transcraniana por corrente contínua (ETCC) para tratar os sintomas negativos da esquizofrenia. Métodos O estudo STARTS foi concebido como um ensaio clínico randomizado, controlado por simulação, duplo-cego, avaliando a ETCC para o tratamento dos sintomas negativos da esquizofrenia. Cem pacientes serão incluídos e submetidos a 10 sessões de ETCC sobre o córtex pré-frontal dorsolateral esquerdo (estimulação anódica) e a junção temporoparietal esquerda (estimulação catodal) durante 5 dias consecutivos. Os participantes serão avaliados através de testes clínicos e neuropsicológicos antes e após a intervenção. O desfecho primário é a mudança na pontuação da subescala negativa da Escala da Síndrome Positiva e Negativa (Positive and Negative Syndrome Scale [PANSS]) ao longo do tempo e entre os grupos. Marcadores biológicos, incluindo neurotrofinas e interleucinas do sangue, polimorfismos genéticos e excitabilidade cortical motora, também serão avaliados. Resultados Os resultados clínicos fornecerão informações sobre a ETCC como um tratamento para os sintomas negativos da esquizofrenia, e a investigação dos biomarcadores contribuirá para uma melhor compreensão dos mecanismos de ação da ETCC. Conclusão Nossos resultados podem trazer uma nova técnica terapêutica para o tratamento dos sintomas negativos da esquizofrenia. Registro do ensaio clínico: ClinicalTrials.gov, NCT02535676.

Palavras-chave

Esquizofrenia, terapia de estimulação elétrica, ensaio clínico randomizado, marcadores biológicos, estimulação transcraniana

References

Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39:789-94.

Ananth J, Djenderdjian A, Shamasunder P, Costa J, Herrera J, Sramek J. Negative symptoms: psychopathological models. J Psychiatry Neurosci. 1991;16:12-8.

Crow TJ. Brain changes and negative symptoms in schizophrenia. Psychopathology. 1995;28:18-21.

Anthony WA, Jansen MA. Predicting the vocational capacity of the chronically mentally ill. Research and policy implications. Am Psychol. 1984;39:537-44.

Bowen L, Wallace CJ, Glynn SM, Nuechterlein KH, Lutzker JR, Kuehnel TG. Schizophrenic individuals’ cognitive functioning and performance in interpersonal interactions and skills training procedures. J Psychiatr Res. 1994;28:289-301.

Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry. 1994;151:351-6.

Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol. 2005;20:199-205.

Sarkar S, Hillner K, Velligan DI. Conceptualization and treatment of negative symptoms in schizophrenia. World J Psychiatry. 2015;5:352-61.

Kishimoto H, Yamada K, Iseki E, Kosaka K, Okoshi T. Brain imaging of affective disorders and schizophrenia. Psychiatry Clin Neurosci. 1998;52(^sSuppl):S212-4.

Cohen JD, Perlstein WM, Braver TS, Nystrom LE, Noll DC, Jonides J. Temporal dynamics of brain activation during a working memory task. Nature. 1997;386:604-8.

Sabri O, Erkwoh R, Schreckenberger M, Cremerius U, Schulz G, Dickmann C. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J Nucl Med. 1997;38:181-8.

Andreasen NC, O’Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997;349:1730-4.

Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol. 2002;5:73-103.

Eisenegger C, Treyer V, Fehr E, Knoch D. Time-course of “off-line” prefrontal rTMS effects--a PET study. Neuroimage. 2008;42:379-84.

Le YY, Qian GZ, Sui LM, Gong QZ, Xu RB. Low-affinity binding sites of glucocorticoid. Zhongguo Yao Li Xue Bao. 1991;12:358-62.

Rollnik JD, Huber TJ, Mogk H, Siggelkow S, Kropp S, Dengler R. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport. 2000;11:4013-5.

Sachdev P, Loo C, Mitchell P, Malhi G. Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry Clin Neurosci. 2005;59:354-7.

Sommer IE, Weijer AD, Daalman K, Neggers SF, Somers M, Kahn RS. Can fMRI-guidance improve the efficacy of rTMS treatment for auditory verbal hallucinations?. Schizophr Res. 2007;93:406-8.

Schonfeldt-Lecuona C, Gron G, Walter H, Buchler N, Wunderlich A, Spitzer M. Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. Neuroreport. 2004;15:1669-73.

Poulet E, Brunelin J, Bediou B, Bation R, Forgeard L, Dalery J. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biol Psychiatry. 2005;57:188-91.

McIntosh AM, Semple D, Tasker K, Harrison LK, Owens DG, Johnstone EC. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Res. 2004;127:9-17.

Loo CK, Sainsbury K, Mitchell P, Hadzi-Pavlovic D, Sachdev PS. A sham-controlled trial of left and right temporal rTMS for the treatment of auditory hallucinations. Psychol Med. 2010;40:541-6.

Lee SH, Kim W, Chung YC, Jung KH, Bahk WM, Jun TY. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations. Neurosci Lett. 2005;376:177-81.

Hajak G, Marienhagen J, Langguth B, Werner S, Binder H, Eichhammer P. High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychol Med. 2004;34:1157-63.

Blumberger DM, Fitzgerald PB, Mulsant BH, Daskalakis ZJ. Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia. Curr Opin Psychiatry. 2010;23:85-90.

Cohen E, Bernardo M, Masana J, Arrufat FJ, Navarro V, Valls S. Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. J Neurol Neurosurg Psychiatry. 1999;67:129-30.

Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry. 2010;71:873-84.

Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry. 2010;71:411-8.

Fregni F, Pascual-Leone A. Technology insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS. Nat Clin Pract Neurol. 2007;3:383-93.

Nitsche MA, Boggio PS, Fregni F, Pascual-Leone A. Treatment of depression with transcranial direct current stimulation (tDCS): a review. Exp Neurol. 2009;219:14-9.

Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol. 2008;11:249-54.

Lefaucheur JP, Antal A, Ayache SS, Benninger DH, Brunelin J, Cogiamanian F. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. 2017;128:56-92.

Miranda PC, Lomarev M, Hallett M. Modeling the current distribution during transcranial direct current stimulation. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2006;117:1623-9.

Wagner T, Fregni F, Fecteau S, Grodzinsky A, Zahn M, Pascual-Leone A. Transcranial direct current stimulation: a computer-based human model study. Neuroimage. 2007;35:1113-24.

Bindman LJ, Lippold OC, Redfearn JW. The Action of Brief Polarizing Currents on the Cerebral Cortex of the Rat (1) during Current Flow and (2) in the Production of Long-Lasting after-Effects. J Physiol. 1964;172:369-82.

Priori A, Hallett M, Rothwell JC. Repetitive transcranial magnetic stimulation or transcranial direct current stimulation?. Brain Stimul. 2009;2:241-5.

Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012;169:719-24.

Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32:715-23.

Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. The International Journal of Neuropsychopharmacology. 2011;14:1133-45.

Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2006;117:845-50.

Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clin Neurophysiol. 2006;117:845-50.

Cordes J, Thunker J, Agelink MW, Arends M, Mobascher A, Wobrock T. Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on clinical global impression in chronic schizophrenia. Psychiatry Res. 2010;177:32-6.

Gur RC, Richard J, Hughett P, Calkins ME, Macy L, Bilker WB. A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation. J Neurosci Methods. 2010;187:254-62.

Nieto R, Kukuljan M, Silva H. BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory. Front Psychiatry. 2013;4.

Rybakowski JK, Borkowska A, Skibinska M, Szczepankiewicz A, Kapelski P, Leszczynska-Rodziewicz A. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin Neurosci. 2006;60:70-6.

Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res. 2007;41:31-5.

Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett. 2005;382:27-32.

Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry. 2015;20:1108-19.

Palomino A, Vallejo-Illarramendi A, González-Pinto A, Aldama A, González-Gómez C, Mosquera F. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res. 2006;86:321-2.

Radhu N, Jesus DR, Ravindran LN, Zanjani A, Fitzgerald PB, Daskalakis ZJ. A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders. Clin Neurophysiol. 2013;124:1309-20.

Chen R, Cros D, Curra A, Di Lazzaro V, Lefaucheur JP, Magistris MR. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol. 2008;119:504-32.

Harrison PJ. Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol. 2015;29:85-96.

Windhoff M, Opitz A, Thielscher A. Electric field calculations in brain stimulation based on finite elements: an optimized processing pipeline for the generation and usage of accurate individual head models. Hum Brain Mapp. 2013;34:923-35.

Saturnino GB, Antunes A, Thielscher A. On the importance of electrode parameters for shaping electric field patterns generated by tDCS. Neuroimage. 2015;120:25-35.

Brunoni AR, Shiozawa P, Truong D, Javitt DC, Elkis H, Fregni F. Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. Expert Rev Med Devices. 2014;11:383-94.

Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012;169:719-24.

6165fbe5a953951622316c24 trends Articles
Links & Downloads
2238-0019 (Electronic)
Trends Psychiatry Psychother ©2024 All rights reserved.

Trends Psychiatry Psychother

Share this page
Page Sections